Biotech · Private company
Impact Therapeutics, Inc.
Track this companyFree. Adds Impact Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- IMP4297(senaparib)Phase 2 · Advanced Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
- IMP9064Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- SenaparibPhase 2 · mCRPCClinicalTrials.gov · fetched Nov 12, 2026
- IMP7068Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.PHASE1_PHASE2 · RECRUITING · started Apr 30, 2025ClinicalTrials.gov NCT06907043 · fetched Nov 12, 2026
- A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Dec 11, 2023ClinicalTrials.gov NCT06253130 · fetched Nov 12, 2026
- Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Feb 11, 2022ClinicalTrials.gov NCT05269316 · fetched Nov 12, 2026
- Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel TreatmentPHASE2 · UNKNOWN · started Dec 31, 2021ClinicalTrials.gov NCT04822961 · fetched Nov 12, 2026
- The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid TumorsPHASE1 · UNKNOWN · started Feb 25, 2021ClinicalTrials.gov NCT04768868 · fetched Nov 12, 2026
- IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung CancerPHASE1_PHASE2 · COMPLETED · started Aug 7, 2020ClinicalTrials.gov NCT04434482 · fetched Nov 12, 2026